Journal: Molecular nutrition & food research
Article Title: The BASALIT multicenter trial: Gly m 4 quantification for consistency control of challenge meal batches and toward Gly m 4 threshold data.
PMID/MRN: 27748994
Publication Date: 2016-Oct-17
Abstract:
The BASALIT clinical trial (EudraCT 2009-011737-27) investigated efficacy of birch allergen immunotherapy on lowest observed adverse effect levels after soy food challenge in patients with birch-associated and GlyÊmÊ4 allergen mediated soy allergy. Thus, consistently stable GlyÊmÊ4 levels were required in standardized challenge meals.
Soy meal included soy protein isolate (SPI, 88% total protein). A GlyÊmÊ4 specific ELISA was developed and validated. Six SPIs and 24 meal batches were analyzed for GlyÊmÊ4. (Repeated-measures) analyses of variance were done to identify potential changes between batches and time intervals. GlyÊmÊ4 was below the ELISA detection limit (2Êng/mL) in placebo batches. With <20% mean coefficient of variation, GlyÊmÊ4 levels were consistent in 24 soy meal batches and within individual 12-wk shelf-life.
The novel GlyÊmÊ4 specific ELISA proved consistency of challenge meal batches over a 56-month study period. With an average of 178 ?g/g GlyÊmÊ4 in SPI, GlyÊmÊ4 lowest observed adverse effect level can be calculated once clinical lowest observed adverse effect level data based on SPI are available. Hence, sensitivity of patients can be correlated to the relevant allergen content instead of total protein of the allergenic source.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.